Counselors in Ft Washington, MD Accepting Medicare

2 Counselors found. Showing 1 - 2

Rachael Lavon Taylor Counselor Medicare: Not Enrolled in Medicare Practice Location: 7105 Emma Ct, Ft Washington, MD 20744 Phone: 301-204-7415

Sandra Aljami Counselor Medicare: Not Enrolled in Medicare Practice Location: 2305 Rosecroft Blvd, Ft Washington, MD 20744 Phone: 240-463-9409    Fax: 301-686-0192

News Archive

Minn. governor moves forward on insurance exchange, shifts oversight

Minnesota Gov. Mark Dayton is shifting responsibility for a key part of the federal health overhaul in his state - a health insurance exchange - to a different state agency. He's also moving forward on implementing the exchange, he said Tuesday.

Transplantation of pulmonary progenitor cells derived from hESCs promising for acute lung injury

Stem cell researchers exploring a new approach for the care of respiratory diseases report that an experimental treatment involving transplantable lung cells was associated with improved outcomes in tests on mice with acute lung injury. The lung cells were derived from human embryonic stem cells (hESCs). Findings by investigators at The University of Texas Health Science Center at Houston are scheduled to appear in the March issue of Molecular Therapy.

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

Read more Medical News

› Verified 4 days ago